Tradestie Institutional Equity Comparison Engine

MESO vs MCRB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MESO Overall Edge

MESO Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mesoblast Limited American Depositary Shares (MESO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while MCRB counters with relative strength in Valuation. Fundamentally, MESO trades at N/M Forward P/E with -42.6% operating margin (+390.7% YoY revenue) versus MCRB at 10.8x Forward P/E and -3115.1% operating margin (+68.9% YoY). In options structure, MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro) against MCRB sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MCRB
MESO N/M vs MCRB 10.8x Fwd P/E
Growth & Margin Winner MESO
Op Margin -42.6% vs -3115.1% ยท YoY +390.7% vs +68.9%
Momentum & Technical Winner MESO
1Y -16.4% vs -91.5% ยท 52W Pos 6% vs 0%
Options & Structure Winner MESO
UNCLASSIFIED (37th %ile IV) vs BREAKDOWN (22nd %ile IV)
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
1M Return -6.1%
1Y Return -16.42%
Forward P/E N/M
Unified AI Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
MCRB NASDAQ
Seres Therapeutics, Inc.
Pharmaceutical Preparations
$1.42
+1.43% 1D
Market Cap $13.9M
1M Return -42.28%
1Y Return -91.53%
Forward P/E 10.8x
Unified AI Score
52.1 / 100 HOLD
Tech 50.0 Fund 59.0 Flow 66.0 Mom 63.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MESO -16.42% MCRB -91.53% Spread: +75.11 pp (MESO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MESO TTM Op. Margin: -42.6% MCRB TTM Op. Margin: -3115.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs MCRB. Trailing 12-month operating profitability (MESO -42.6% vs MCRB -3115.1%) and valuation multiples (MESO N/M vs MCRB 10.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MESO (6) vs MCRB (4)
Institutional Metric MESO MCRB Criterion Row Winner
Market Capitalization Scale $1.7B $13.9M Larger Scale MESO
Trailing P/E Ratio Valuation N/M 10.8x Lower Multiple MCRB
Forward P/E Ratio Valuation N/M 10.8x Lower Multiple MCRB
Revenue Growth (YoY) Growth +390.7% +68.9% Higher Growth MESO
Operating Margin (TTM) Profitability -42.6% -3115.1% Higher Margin MESO
Net Profit Margin Profitability -47.8% 0.0% Higher Margin MCRB
Return on Equity (ROE) Capital Efficiency -9.9% -144.3% Higher ROE MESO
52-Week Range Position Momentum 6% ($12โ€“$22) 0% ($1โ€“$30) Stronger Trend MESO
Beta / 30D Volatility Risk Regime 1.18ฮฒ ยท 78% Vol 0.64ฮฒ ยท 97% Vol Lower Realized Risk MESO
Unified Institutional Score Composite Signal 34.6 / 100 (SELL) 52.1 / 100 (HOLD) Higher Composite MCRB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MESO vs MCRB Buy Guide
MESO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MESO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MCRB BREAKDOWN
93d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live MCRB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MESO nor MCRB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.